- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05202964
Compliance and Tolerance to Oral AntiBiotherapy in Osteoarticular Infections (OTABIO) (OTABIO)
Compliance and Tolerance to Oral AntiBiotherapy in Osteoarticular Infections
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: Tristan FERRY, MD, PHD
- Phone Number: +33 4 26 73 29 38
- Email: tristan.ferry@chu-lyon.fr
Study Contact Backup
- Name: Eugénie Mabrut
- Phone Number: +33 4 26 73 29 38
- Email: eugenie.mabrut@chu-lyon.fr
Study Locations
-
-
-
Lyon, France, 69004
- Recruiting
- Hospices Civils de Lyon
-
Contact:
- Tristan FERRY
- Phone Number: +33 4 26 73 29 38
- Email: tristan.ferry@chu-lyon.fr
-
Principal Investigator:
- Valérie MIRABET
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- ≥ 18 years
- Diagnosis of osteoarticular infection
- Treatment with at least one oral antibiotic for a minimum expected duration ≥ 6 weeks with an expected end of treatment date
- Patient who was informed and did not object to participate in the study
Exclusion Criteria:
- Treatment for BJI with oral antibiotic without end of treatment date
- treatment for BJI with parenteral antibiotic only
- patient who doesn't have a telephone number or who doesn't want to give it
- Adults subject to a legal protection measure
- Pregnant or breastfeeding women
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Tolerance and adherence to oral antibiotics in patients managed for BJI
Patients having a BJI treated by surgery and taking at least one oral antibiotic after the surgery
|
Adherence and tolerance will be measured 6 weeks (S6) and 3 months (M3) after the surgery. The compliance data collected will be compared by two methods (electronic pill dispensers and questionnaire) Responses to the compliance questionnaire will be collected during a telephone interview by a member of the Croix-Rousse pharmacy at S6 and M3. The pill organizer data from S6 and M3 will be transferred to the software by a nurse. Patients will respond to a questionnaire about the tolerance on the consultation at S6 and M3. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of doses taken at 6 weeks
Time Frame: At 6 weeks after surgery
|
Ratio of the number of doses taken over the theoretical number of doses to be taken over the period
|
At 6 weeks after surgery
|
Percentage of doses taken at 3 months
Time Frame: at 3 months after surgery
|
Ratio of the number of doses taken over the theoretical number of doses to be taken over the period
|
at 3 months after surgery
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Valérie MIRABET, Hospices Civils de Lyon
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 69HCL21_0905
- 2021-A02134-37 (Other Identifier: ID RCB)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Drug-Related Side Effects and Adverse Reactions
-
Texas A&M UniversityInnovativeGx; Texas A&M Health Family Care Clinic; iC42 Clinical Research and... and other collaboratorsRecruiting
-
Leiden University Medical Centerbio.logis digital health GmbHRecruiting
-
Fayoum UniversityCompletedAdverse Drug ReactionEgypt
-
CHU de ReimsCompletedChild With Adverse Drug Reactions
-
Companion Dx Reference Lab, LLCUnknownDrug Side Effects
-
CHU de ReimsCompleted
-
Germans Trias i Pujol HospitalCompletedAdverse Drug Reaction
-
University College CorkCompletedAdverse Drug ReactionIreland
-
University College CorkCompleted
-
Universidade Estadual Paulista Júlio de Mesquita...CompletedAdverse Drug ReactionBrazil
Clinical Trials on Tolerance and adherence to oral antibiotics in patients managed for BJI
-
University Hospital, Basel, SwitzerlandCompletedInfectious Diseases and ManifestationsSwitzerland
-
Gonul Kara SoylemezCompleted
-
Eskisehir Osmangazi UniversityRecruiting
-
Hospices Civils de LyonCompletedOral Glucose Tolerance Test and Post Partum Diagnosis of Diabetes Mellitus, Type 2 (DT2 Post-Partum)Gestational DiabetesFrance
-
University of CopenhagenResearch Unit for General Practice, Aarhus University; Slagelse Hospital; Research... and other collaboratorsNot yet recruitingMultimorbidityDenmark
-
PerspectumActive, not recruitingLiver Cancer | Liver Metastasis Colon CancerUnited Kingdom
-
Assistance Publique - Hôpitaux de ParisPfizerRecruitingSickle Cell DiseaseFrance
-
Hospices Civils de LyonWithdrawnCardiovascular Diseases
-
Instituto de Investigacion Sanitaria La FeSociedad Española de Neumología y Cirugía Torácica; Sociedad Valenciana de... and other collaboratorsRecruitingCommunity-acquired PneumoniaSpain
-
Cairo UniversityCompleted